These results indicate that RXRA ligands improve IM sensitivity by decreasing the BCR-ABL downstream signaling pathways and increasing apoptosis in CML primary cells and cell lines. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.